Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Common Equity (2016 - 2025)

Nephros has reported Common Equity over the past 16 years, most recently at $10.2 million for Q4 2025.

  • Quarterly results put Common Equity at $10.2 million for Q4 2025, up 18.84% from a year ago — trailing twelve months through Dec 2025 was $10.2 million (up 18.84% YoY), and the annual figure for FY2025 was $10.2 million, up 18.84%.
  • Common Equity for Q4 2025 was $10.2 million at Nephros, up from $10.0 million in the prior quarter.
  • Over the last five years, Common Equity for NEPH hit a ceiling of $15.5 million in Q1 2021 and a floor of $7.9 million in Q2 2024.
  • Median Common Equity over the past 5 years was $9.4 million (2022), compared with a mean of $10.6 million.
  • Biggest five-year swings in Common Equity: soared 34.0% in 2021 and later crashed 39.79% in 2022.
  • Nephros' Common Equity stood at $14.7 million in 2021, then crashed by 39.79% to $8.9 million in 2022, then decreased by 5.89% to $8.4 million in 2023, then increased by 2.72% to $8.6 million in 2024, then rose by 18.84% to $10.2 million in 2025.
  • The last three reported values for Common Equity were $10.2 million (Q4 2025), $10.0 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.